These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 19325448)

  • 21. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease.
    Pizzutto SJ; Yerkovich ST; Upham JW; Hales BJ; Thomas WR; Chang AB
    Vaccine; 2015 Jan; 33(2):321-6. PubMed ID: 25448103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines.
    Forsgren A; Riesbeck K; Janson H
    Clin Infect Dis; 2008 Mar; 46(5):726-31. PubMed ID: 18230042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.
    Madhi SA; Koen A; Jose L; van Niekerk N; Adrian PV; Cutland C; François N; Ruiz-Guiñazú J; Yarzabal JP; Moreira M; Borys D; Schuerman L
    Medicine (Baltimore); 2017 Jan; 96(2):e5881. PubMed ID: 28079828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
    Plosker GL
    Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
    Schuerman L; Prymula R; Henckaerts I; Poolman J
    Vaccine; 2007 Mar; 25(11):1962-8. PubMed ID: 17258357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.
    Lim FS; Koh MT; Tan KK; Chan PC; Chong CY; Shung Yehudi YW; Teoh YL; Shafi F; Hezareh M; Swinnen K; Borys D
    BMC Infect Dis; 2014 Oct; 14():530. PubMed ID: 25278086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice.
    Siggins MK; Gill SK; Langford PR; Li Y; Ladhani SN; Tregoning JS
    Vaccine; 2015 Sep; 33(38):4954-61. PubMed ID: 26212006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
    Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of the immune response following pneumococcal PD conjugate vaccination.
    Schuerman L; Prymula R; Chrobok V; Dieussaert I; Poolman J
    Vaccine; 2007 Mar; 25(11):1953-61. PubMed ID: 17258358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
    Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
    Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
    Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol.
    Prymula R; Habib A; François N; Borys D; Schuerman L
    Vaccine; 2013 Apr; 31(16):2080-8. PubMed ID: 23391599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
    J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
    Hare KM; Smith-Vaughan HC; Leach AJ; Pizzutto SJ; McCallum GB; Chang AB
    Vaccine; 2018 Mar; 36(13):1736-1742. PubMed ID: 29478754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.
    Prymula R; Schuerman L
    Expert Rev Vaccines; 2009 Nov; 8(11):1479-500. PubMed ID: 19863240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
    Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
    PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
    Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D
    Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Borys D; Lommel P; Traskine M; Moreira M; Schuerman L; Kilpi TM
    Lancet Infect Dis; 2014 Mar; 14(3):205-12. PubMed ID: 24287186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.
    Clarke C; Bakaletz LO; Ruiz-Guiñazú J; Borys D; Mrkvan T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-14. PubMed ID: 28571504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.